Navigation Links
BiOptix continues support of Colorado-based research institutions

BOULDER, Colo., June 15, 2012 /PRNewswire/ -- BiOptix, a Colorado-based firm, announces completion of a successful week of research shows in Colorado's Biotech Corridor.

BiOptix today announced support of events this week at National Jewish Health, the University of Colorado Denver-Anschutz Medical Campus and at the University of Colorado, Boulder.  These events brought Colorado-based researchers together with representatives of dozens of global life science research suppliers, and are a critical link in the research supply and innovation chain.  The strength and participation at these events highlight the significant research activities that exist in Colorado, and BiOptix, as a Boulder, Colorado-based company is proud to support the continued development and expansion of these efforts. 

Supporting Colorado's Growing Biotech Corridor—and our hometown of Boulder.     

Colorado's growing biotech corridor is concentrated in the Denver-Boulder metropolitan areas allowing BiOptix strategic access to these markets.  "After completing a successful show at the University of California San Francisco, last week, we are excited to turn our attention toward our home market of Colorado for this series of events," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are grateful to have the support of our colleagues in Denver and especially in our hometown of Boulder. Colorado represents a significant opportunity to us as a supplier, not to mention what Colorado means to the global research community—it is awesome to be here."

BiOptix Events

So far in 2012, BiOptix has participated in 8 nation-wide life science industry events and has showcased a novel and patented ultra-sensitive biosensor platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional Surface Plasmon Resonance, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.  BiOptix anticipates more than 30 customer facing events in 2012, with additional planned in 2013.

About BiOptix

BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance.  BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:

SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Profil Institute Continues to Publish New Findings in Metabolic Research
2. AMPAC Fine Chemicals Continues to Invest in Quality Systems
3. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
4. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
5. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
6. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
7. Fluke Biomedical training center goes global: adds multi-language support
8. MDA Supports Development of Dissociative Glucocorticoid for DMD
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
11. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... LifeTrak ... the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to ... offers flexwear technology and accurate heart rate monitoring both in water and ...
Breaking Biology Technology:
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):